國際婦產科聯盟對於 NIPT 提出聲明 

 

Clinical implementation of cfDNA testing should preferably be in a contingent strategy based on the results of first-line screening by the combined test at 11-13 weeks of gestation. In this case, we recommend the strategy below：

• Combined test risk over 1 in 100：patient can be offered the options of cfDNA testing or invasive testing.

• Combined test risk between 1 in 101 and 1 in 2500：patients can be offered the option of cfDNA testing.

• Combined test risk lower than 1 in 2500：there is no need for further testing.